BioSpace News Archive

Sanofi Global Health announces the launch of Impact®, a new brandof standard of care medicines produced by Sanofidedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries.

The latest developments in Octapharma’s haematology and critical care portfolios will be presented at the 30th International Society on Thrombosis and Haemostasis Congress on July 9–13, 2022, in London, UK.

Amsterdam, the Netherlands – Royal Philips announced that it has completed the cancellation of 8,758,455 of its shares.

JW Therapeutics, an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of phase I clinical study of JWATM204 in patients with advanced hepatocellular carcinoma.

Pfizer Canada announces that Health Canada has approved CIBINQO® for the treatment of patients 12 years and older with refractory moderate to severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to other systemic drugs, or for whom these treatments are not advisable.

Arctic Vision announced that the first patient has been enrolled in a Phase III clinical study evaluating ARVN003, a proprietary pilocarpine formulation leveraging its micro dosing platform Optejet®, as a treatment to temporarily improve vision in adults with presbyopia in China.

Biosynth Carbosynth (“Biosynth”), a supplier of critical products and services to the life sciences industry, announces today the acquisition of Pepscan, an expert provider of peptide-based products & services.